Evidence map›Paper›PMID 30197955›Full record

ArticleJournal of current ophthalmology2018

Role of combined phacoemulsification and intravitreal injection of bevacizumab in prevention of postoperative macular edema in non-proliferative diabetic retinopathy.

Alireza Khodabandeh, Shahed Fadaifard, Ali Abdollahi, Reza Karkhaneh, Ramak Roohipoor, Fatemeh Abdi, Hamed Ghasemi, Sam Habibollahi, Mehdi Mazloumi

Open access · diamondAbstract read
In one paragraph

Article in Journal of current ophthalmology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Alireza KhodabandehEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Shahed FadaifardEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ali AbdollahiEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Reza KarkhanehEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Ramak RoohipoorEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Fatemeh AbdiEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Hamed GhasemiEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Sam HabibollahiEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Mehdi MazloumiEye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
Farabi Hospital · IR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo evaluate the role of combined phacoemulsification and intravitreal injection of bevacizumab in prevention of postoperative diabetic macular edema (DME) in patients with no diabetic retinopathy or non-proliferative diabetic retinopathy (NPDR) and without macular edema.

methodsIn a prospective randomized clinical trial, 71 eyes from 71 diabetic patients with no diabetic retinopathy or mild NPDR and with central macular thickness (CMT) of less than 300 μm were enrolled and were randomized into two groups: combined phacoemulsification and intravitreal bevacizumab injection group and only phacoemulsification group. Our primary outcome measures included best corrected visual acuity (BCVA), CMT, and total macular volume (TMV) before and after (1 month and 3 months) the cataract surgery.

resultsThe two groups did not show any significant difference in terms of baseline BCVA, age, CMT, stage of diabetic retinopathy. While the bevacizumab group showed lower CMT one month after the surgery compared to control group (267.3 ± 31.8 and 293.6 ± 53.7, respectively,

conclusionsAlthough the intravitreal injection of bevacizumab during phacoemulsification would result in decreased macular thickness in patients with no diabetic retinopathy or NPDR and without macular edema in the early postoperative period, this effect would no longer persistent at 3 months. In addition, the BCVA and TMV showed no significant difference between the two groups at any time during follow-up period.

Indexed as

Intravitreal bevacizumabPhacoemulsificationPostoperative macular edema

Identifiers

PMID30197955
PMCPMC6127363
OpenAlexW2799525070

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.